Phillips-Medisize, Dance Biopharm ink deal for inhaled insulin device

Share

Phillips-MedisizePrivately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin.

The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it gets to the market.

The Dance 501 device stores a liquid formulation of recombinant human insulin in a dispenser with a hand-held electronic inhaler. The device uses vibrating mesh to produce particles of liquid insulin in a soft mist.

Get the full story on our sister site Drug Delivery Business News.

Join the Best Minds in MedTech at DeviceTalks Minnesota!

textadimage This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.

ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.

Take a look at our full agenda.

Use the code "TRACKS" to save 15% on the cost of registration. 

REGISTER TODAY

Speak Your Mind

*